INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 211 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,202 | -17.7% | 656,569 | +0.0% | 0.01% | -16.7% |
| Q2 2023 | $41,562 | +41.1% | 656,358 | +20.7% | 0.01% | +50.0% |
| Q1 2023 | $29,455 | +4.6% | 543,934 | +2.2% | 0.00% | -20.0% |
| Q4 2022 | $28,160 | -99.8% | 532,137 | +51.6% | 0.01% | +66.7% |
| Q3 2022 | $16,331,000 | +602.1% | 350,956 | +761.4% | 0.00% | – |
| Q2 2022 | $2,326,000 | -4.2% | 40,742 | +2.6% | 0.00% | – |
| Q1 2022 | $2,429,000 | +28.2% | 39,702 | +9.7% | 0.00% | – |
| Q4 2021 | $1,894,000 | +25.3% | 36,189 | -10.7% | 0.00% | – |
| Q3 2021 | $1,511,000 | +2.2% | 40,522 | +11.8% | 0.00% | – |
| Q2 2021 | $1,479,000 | +8.2% | 36,243 | -10.0% | 0.00% | – |
| Q1 2021 | $1,367,000 | +36.6% | 40,289 | +27.9% | 0.00% | – |
| Q4 2020 | $1,001,000 | -87.5% | 31,490 | -90.0% | 0.00% | -100.0% |
| Q3 2020 | $8,040,000 | -67.4% | 313,346 | -67.4% | 0.00% | -66.7% |
| Q2 2020 | $24,688,000 | +7.5% | 961,749 | -35.6% | 0.00% | -25.0% |
| Q1 2020 | $22,970,000 | -48.2% | 1,494,485 | +15.6% | 0.00% | -33.3% |
| Q4 2019 | $44,371,000 | +8086.5% | 1,293,236 | +1681.9% | 0.01% | – |
| Q3 2019 | $542,000 | -88.3% | 72,578 | -79.6% | 0.00% | -100.0% |
| Q2 2019 | $4,614,000 | +6.4% | 355,500 | -0.2% | 0.00% | 0.0% |
| Q1 2019 | $4,337,000 | +8.5% | 356,063 | +1.5% | 0.00% | 0.0% |
| Q4 2018 | $3,997,000 | -58.3% | 350,963 | -20.4% | 0.00% | 0.0% |
| Q3 2018 | $9,574,000 | -35.6% | 441,178 | -47.6% | 0.00% | -50.0% |
| Q2 2018 | $14,864,000 | -38.3% | 841,188 | -26.4% | 0.00% | -50.0% |
| Q1 2018 | $24,074,000 | +6700.6% | 1,143,640 | +4580.1% | 0.00% | – |
| Q4 2017 | $354,000 | +35.6% | 24,436 | +47.8% | 0.00% | – |
| Q3 2017 | $261,000 | +48.3% | 16,536 | +17.0% | 0.00% | – |
| Q2 2017 | $176,000 | -97.8% | 14,136 | -97.1% | 0.00% | -100.0% |
| Q1 2017 | $7,854,000 | +0.7% | 483,311 | -6.4% | 0.00% | -50.0% |
| Q4 2016 | $7,796,000 | -9.3% | 516,622 | -8.4% | 0.00% | 0.0% |
| Q3 2016 | $8,591,000 | +2203.2% | 563,702 | +5767.6% | 0.00% | – |
| Q2 2016 | $373,000 | +40.2% | 9,607 | +0.4% | 0.00% | – |
| Q1 2016 | $266,000 | – | 9,570 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |